JohnColeMD

Oncology • New Orleans, LA

Breast Cancer, Hematologic Oncology

Chairman, Department of Hematology and Medical Oncology Ochsner South Shore Clinics

Join to view full profile

Dr. Cole is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cole's full profile

Already have an account?

Office
Gayle & Tom Benson Cancer Center
1514 Jefferson Highway
New Orleans, LA 70121
Phone+1 504-842-3910

Fax+1 504-842-4533

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1984 - 1987
Ochsner Clinic FoundationResidency, Internal Medicine, 1981 - 1984
Louisiana State University School of Medicine in New OrleansClass of 1981, MD

Certifications & Licensure

LA State Medical License 1981 - 2025
MS State Medical License 2020 - 2021
AL State Medical License 2020 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Start of enrollment: 2017 Mar 31
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience.
Julia Levy, Fady Farag, John Cole
Breast Cancer Research and Treatment. 2022-11-01
56 citations
Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana.
Michael Lunski, Jeffrey H. Burton, Karine Tawagi, Diana Maslov, Victoria Simenson
Cancer. 2021-01-15
58 citations
Endocrine Therapy for Early Breast Cancer: Updated Review.
Alexander Tremont, Jonathan J. Lu, John T. Cole
Ochsner Journal. 2017-01-01

Journal Articles

A Phase 1 Study of a Combination of Allopurinol, 5-Fluourouracil and Leucovorin Followed by Hydroxyeurea in patients with Advanced Gastrointestinal and Breast Cancer.
Phase 1 Study of a Combination of Allopurinol, 5-Fluourouracil and Leucovorin Followed by Hydroxyeurea in patients with Advanced Gastrointestinal and Breast Cancer., American Journal of Clinical Oncology, 1991
Effects in vitro of 2’deoxycytidine on the Metabolism and Cytotoxicity of 2’3’-dideoxycytidine.
7. Bhalla KN, Gongrong L, Grant S, Cole J, MacLaughlin WW, and Volsky DJ, Aids, 1990
Reversal of continuously administered high dose ara-c mediated toxicity by deoxycytidine in cultured human leukemia and normal human myeloid progenitors.
1. Bhalla K, MacLaughlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S, Blood, 1985